SUN PHARMA ADV.RES.CO.LTD Quarterly Results (SPARC) — Q1 FY27

Revenue trend and demand read-through

Topline for Q1 FY27 came in at ₹39.92 cr against ₹9.64 cr in Q1 FY26, and ₹1,853 cr in the preceding Q4 FY26 quarter.

On a sequential basis revenue declined -97.8%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.

Total expenses for the quarter were ₹76.12 cr, or 190.7% of revenue, with operating profit grew +33.9% year on year.

Margins, tax and profitability

Net profit of -₹20.78 cr works out to a net margin of -52.1% compared with -538.1% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.

Below the operating line, SUN PHARMA ADV.RES.CO.LTD reported profit before tax of -₹20.67 cr, a tax charge of ₹0.11 cr (effective rate -0.5%), interest cost of ₹8.13 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.

Sequentially, net profit moved from ₹1,761 cr in Q4 FY26 to -₹20.78 cr in Q1 FY27, a change of -101.2%.

Trailing twelve months and annual context

Across the trailing four quarters SUN PHARMA ADV.RES.CO.LTD has generated revenue of ₹1,909 cr and net profit of ₹1,584 cr, a trailing net margin of 83.0%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.

On a full-year basis, FY26 revenue was ₹39.15 cr with net profit of ₹1,553 cr and EPS of ₹47.86, versus the prior year where revenue declined -45.5% and profit grew +553.5%.

What to watch in the next SPARC quarter

For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.

SUN PHARMA ADV.RES.CO.LTD has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.

All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.